HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon? (Q38174259)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373087%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373087%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373087%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Jia-Horng Kao

1 reference

30 August 2017

publication date

1 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373087%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373087%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

34 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373087%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

112-119

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373087%20AND%20SRC:MED&resulttype=core&format=json

Global control of hepatitis B virus infection.

3 March 2020

cites work

1 reference

Recent advances in the research of hepatitis B virus-related hepatocellular carcinoma: epidemiologic and molecular biological aspects

21 January 2018

1 reference

Chronic hepatitis B: update 2009

21 January 2018

1 reference

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

21 January 2018

1 reference

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

21 January 2018

1 reference

Recent advances in the treatment of chronic hepatitis B.

21 January 2018

1 reference

High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study

21 January 2018

1 reference

Pegylated interferons for chronic hepatitis B.

21 January 2018

1 reference

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b

21 January 2018

1 reference

Endpoints of therapy in chronic hepatitis B.

21 January 2018

1 reference

Management of hepatitis B: summary of a clinical research workshop

21 January 2018

1 reference

A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

Hepatitis B viral factors and treatment responses in chronic hepatitis B.

21 January 2018

1 reference

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

Risk stratification for hepatitis B virus related hepatocellular carcinoma

21 January 2018

1 reference

Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature

21 January 2018

1 reference

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

21 January 2018

1 reference

The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B

21 January 2018

1 reference

Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers

21 January 2018

1 reference

Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective.

21 January 2018

1 reference

Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B.

21 January 2018

1 reference

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline

21 January 2018

1 reference

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels

21 January 2018

1 reference

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Molecular epidemiology of hepatitis B virus

21 January 2018

1 reference

The clinical implications of hepatitis B virus genotype: Recent advances.

21 January 2018

1 reference

Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J.

21 January 2018

1 reference

Appropriate use of interferon for treatment of chronic hepatitis B.

21 January 2018

1 reference

Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a

21 January 2018

1 reference

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa

21 January 2018

1 reference

Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion.

21 January 2018

1 reference

Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels

21 January 2018

1 reference

Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog.

21 January 2018

1 reference

Host genetics and the outcome of hepatitis B viral infection

21 January 2018

1 reference

A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians

21 January 2018

1 reference

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

Genomic variation-guided management in chronic hepatitis C.

21 January 2018

1 reference

New perspectives in the therapy of chronic hepatitis B.

21 January 2018

1 reference

Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy

21 January 2018

1 reference

Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study

21 January 2018

1 reference